Business Wire

Next Gen Video Meets Reality at IBC2018

Del

Technology companies and service providers will once again come together to discuss the latest trends, strategies and developments in online TV and video at the Content Everywhere Hub programme at IBC2018, it has been announced today. As the latest addition to the agenda for IBC2018, the world’s most influential media, entertainment and technology show (to be held from 13-18 September at the RAI in Amsterdam), the IBC Content Everywhere Hub will consist of 10 expert panel discussions and 34 product demos.

Situated at the heart of IBC2018 in Hall 14, IBC Content Everywhere combines a high-quality exhibition with the Hub programme designed to help visitors learn and experience how innovative new technologies are expanding the opportunities arising from the exponential growth of content consumption online.

The agenda for the Hub is centered on 10 panel discussions drawing together a range of perspectives and expertise on key issues including the implications for the digital media sector of high profile emerging technologies such as 5G, Edge computing and blockchain. Other topics covered will include how to successfully grow an OTT service, how artificial intelligence and machine learning are impacting content creation, OTT distribution and monetisation, new business models and innovations in programmatic advertising, as well as the convergence of broadcast and telecoms.

There will also be 34 product demonstrations covering the entire OTT distribution chain, including online video platforms, transcoding and streaming solutions, content security options and monetisation techniques. Speakers will include experts from small start-ups to some of the biggest names in technology including Google, Alibaba, CSGi, Telia, Ooyala and Roku.

With viewers wishing to take greater control over their viewing habits, over-the-top distribution is becoming more and more critical to the electronic media eco-system. Offering consumers ‘content everywhere’ and catch-up services are now essential requirements for many broadcasters to complement traditional distribution, as well as telcos wanting to add video to their portfolios or independent content creators or brands wishing to go direct-to-consumer. The ability to deliver content ‘over the top’ across broadband networks has also opened the door for new players to establish their own direct relationships with new audiences. IBC Content Everywhere will bring together technology companies and service providers who are at the heart of this revolution

## ENDS ##

Notes to Editors:

For more information about IBC2018 visit: show.ibc.org

About IBC
IBC is the world’s most influential media, entertainment and technology show, attracting 57,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.

IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.

IBC2018 Dates
Conference: 13 - 17 September 2018
Exhibition: 14 - 18 September 2018

For more information about IBC2018 visit: show.ibc.org/

Contact information

IBC
Louise Wells, Bubble Agency
E: louisew@bubbleagency.com
T: +44 7718 985 252

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 10:18:00 CESTPressemelding

The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 10:00:00 CESTPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc

Enterprise Integration Middleware Leader, Fiorano Software, Announces Release of Fiorano Platform 12.024.4.2019 09:00:00 CESTPressemelding

Fiorano Software, a leader in Integration Middleware, API Management and peer-to-peer distributed systems, announced today the release of version 12.0 of the Fiorano ESB and API Management platform. The latest release with new adapters and tools includes enhanced and optimised features to improve performance of its servers delivering a more productive SOA and API Management deployment with a significant incremental return on investment. The platform offers a unified profile to run all Fiorano Servers in a single process and ships with several new adapters including a Kafka Connector, DynamoDB, AS4Connector, SMPPSend and WebSockets. Users can now import Event Processes directly from the Dashboard and optimize CRC processes by fetching components from local repositories. The new platform provides a new HTML5 dashboard, monetisation and security policies like JWT/JWS for API Management while supporting Open API specifications, OpenId Connect and time-based accessing and quota policies alo

Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™24.4.2019 08:30:00 CESTPressemelding

Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019. SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization. It is the intention of the Smart Pharma group to continue to incorporate Aenco’s blockchain technology into its pharmaceutical development and commercialization processes. Relying on intellectual property derived from the Smart-ACT™ platform, Smart Pharma’s in-house new and repurposed

Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases24.4.2019 08:30:00 CESTPressemelding

Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005095/en/ (Photo: Business Wire) Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACTTM platform will initially focus on the screening drug molecules for orphan diseases or unmet medical needs. To date, SmartP has, under the recently established

Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 201924.4.2019 08:15:00 CESTPressemelding

Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-negotiated transaction, repurchased all outstanding US$13,500,000 in aggregate principal amount of the 8.00 per cent. convertible bonds due 2019 (“Convertible Bonds”) from Peace Range Limited, a wholly owned subsidiary of Adamas Ping An Opportunities Fund LP, together with certain subscription right to subscribe up to the principal amount of the Bond at a US$12.17 (subject to adjustment) on or before December 17, 2019 (“Subscription Right”). The total consideration of the repurchase of the Convertible Bonds and the Subscription Right was US$13.6 million in cash, excluding accrued interest. The repurchase of the Convertible Bonds and Subscription Right was executed by Aptorum Investment Holding Limited, a wholly owned subsidiary